• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    BioCorRx Shares Financial Results for Q2 2017

    Bryan Mc Govern
    Aug. 16, 2017 08:44AM PST
    Pharmaceutical Investing

    BioCorRx released their financial report for the second quarter of 2017 and provided a business update to shareholders.

    BioCorRx (OTCQB:BICX) released their financial report for the second quarter of 2017 and provided a business update to shareholders.
    As quoted in the press release:

    Brady Granier, President, CEO, and Director, stated, “We are pleased to report a 12% increase in revenue for the second quarter ended June 30, 2017. The increase in revenue is due to the increased number of clinics, as well as patients treated at clinics already licensed to offer our BioCorRx Recovery Program. In July, we entered into agreements with centers in three different states that will be implementing the BioCorRx Recovery Program. Our program is a non-addictive, medication-assisted treatment (MAT) program that combines a naltrexone implant with a proprietary counseling program and peer support specifically tailored for the treatment of alcoholism and opioid use disorder. In South Florida, we are now working with Hope Recovery and Wellness in West Palm Beach, which will be the first center in that area to implement the BioCorRx Recovery Program. EnLite™ Clinics is the first center to introduce our program in Ohio (at three locations), which is considered by many to be the epicenter of the opioid crisis. Lastly, we announced that Serrano KVAC clinic, an affiliate of the Serrano Kidney and Vascular Access Center of California, in conjunction with Serrano KVAC’s partner CereCare, LLC, will implement the BioCorRx Recovery Program for the Hispanic market in Los Angeles, California. This marks the first clinic offering our program specifically for the Hispanic market.”

    Click here to read the full press release.

    Source: www.accesswire.com

    pharmaceutical investingbusiness updatebiocorrx recovery programfinancial reportopioid crisis
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×